Facebook Twitter Instagram You Tube Pinterest LinkedIn RSS Podcasts Video Library Blog
 - Northwestern Memorial Hospital - Chicago

Safety & Efficacy of Taribavirin when given with IFN-alfa 2b versus the Standard of Care

Comparison of Weight-based Doses of Taribavirin Combined With Peginterferon Alfa 2b Versus Ribavirin Combined With Peginterferon Alfa-2b in Therapy-naïve Patients With Chronic Hepatitis C Virus Genotype 1 Infection

The primary purpose of this study is evaluate the safety and efficacy of Taribavirin when given with IFN-alfa 2b vs. ribavirin given with IFN-alfa 2b (the standard of care).

Inclusion Criteria:

Naïve No cirrhotics

  • GT 1 -ANC >1200/mm3
  • -PLT >90,000
  • -Hb >13g/dL males >12g/dL females
  • -AFP <20 ng/mL If >20, neg. imaging within 6 mo.

Sponsor:

Valeant Pharmaceuticals

Principle Investigator:

Steve Flamm, MD

Cost:

None

Contact:

Kim Sipich
312-503-0121

Last UpdateMarch 25, 2011
top